Development of acute myocardial infarction in a young female patient with essential thrombocythemia treated with anagrelide: a case reportopen accessDevelopment of acute myocardial infarction in a young female patient with essential thrombocythemia treated with anagrelide: a case report
- Other Titles
- Development of acute myocardial infarction in a young female patient with essential thrombocythemia treated with anagrelide: a case report
- Authors
- 이영열; 임영효; 김재훈; 신진호; 이재웅; 김경수; 김순길; 김정현; 임헌길
- Issue Date
- Jun-2010
- Publisher
- 대한혈액학회
- Keywords
- Anagrelide; Essential thrombocythemia; Acute myocardial infarction
- Citation
- Blood Research, v.45, no.2, pp.136 - 138
- Indexed
- KCI
- Journal Title
- Blood Research
- Volume
- 45
- Number
- 2
- Start Page
- 136
- End Page
- 138
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/174787
- DOI
- 10.5045/kjh.2010.45.2.136
- ISSN
- 2287-979X
- Abstract
- Essential thrombocythemia (ET) is a chronic myeloproliferative disorder with a prolonged clinical course. Since this disorder is considered to be at increased risk of thromboembolism, therapy is mainly focused on the decreased risk of thrombohemorrhagic events by use of cytotoxic agents. Anagrelide is a phosphodiesterase III inhibitor which is utilized in the treatment of ET for the reduction of platelets. However, patients treated with anagrelide might experience cardiovascular adverse effects including myocardial infarction (MI), although these events are rare. Herein, we report a case of a 30-year-old female with well controlled ET by anagrelide, who eventually developed an acute non-ST elevation myocardial infarction (MI). There has no found any cardiovascular risk factors in this ET patient, strongly suggesting that anagrelide might be the cause of MI. Therefore, cardiovascular function should be monitored in those patients prescribed with anagrelide.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.